Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sundeep Adusumalli

Cardiovascular Disease Carmichael, CA Medical Doctor

NPI 1639305295 CMS profile 1292053

6555 Coyle Ave Ste 380, Ste 280, Carmichael, CA 95608

Open in the dashboard

General payments

$12,261

199 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sundeep Adusumalli of Carmichael, CA is reported in the CMS Open Payments database as having received $12,261 across 199 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $857 31
2024 General $1,218 27
2023 General $1,333 44
2022 General $1,511 61
2021 General $411 13
2020 General $2,775 10
2019 General $4,155 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sundeep Adusumalli
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Sundeep Adusumalli were reported at $857. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Sundeep Adusumalli Cardiovascular Disease median Middle half National median
2019 $4,155 $450 $127–$1,392 $163
2020 $2,775 $242 $77–$751 $114
2021 $411 $335 $101–$1,037 $132
2022 $1,511 $395 $121–$1,211 $149
2023 $1,333 $443 $136–$1,283 $160
2024 $1,218 $450 $136–$1,323 $164
2025 $857 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $6,457 14 payments
  2. Medtronic, Inc. $3,241 101 payments
  3. Boston Scientific Corporation $625 36 payments
  4. Abiomed $604 12 payments
  5. Shockwave Medical, Inc $409 11 payments
  6. CryoLife, Inc. $293 2 payments
  7. Medtronic Vascular, Inc. $141 1 payment
  8. Chiesi USA, Inc. $90 3 payments
  9. Abbott Laboratories $88 4 payments
  10. Amgen Inc. $81 3 payments
  11. Other $233 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,000 5 payments
  2. Food and Beverage $5,989 192 payments
  3. Travel and Lodging $272 2 payments
Products named General payments · program years 2019–2025
  1. LifeVest $6,457 14 payments
  2. ONYX FRONTIER $725 17 payments
  3. SYMPLICITY G3 $656 21 payments
  4. FFRANGIO $562 17 payments
  5. Impella $465 11 payments
  6. Telescope $463 17 payments
  7. DxTerity $442 16 payments
  8. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $309 7 payments
  9. On-X $293 2 payments
  10. ACIST RXI SYSTEM $288 8 payments
  11. Other $1,464 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

3,575

Median for Interventional Cardiology: 2,236

Drug cost

$745,084

Median for Interventional Cardiology: $380,412

Branded share of claims

31.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 300 $368,987
Xarelto Rivaroxaban Brand 83 $90,492
Entresto Sacubitril/Valsartan Brand 79 $78,851
Brilinta Ticagrelor Brand 73 $70,340
Repatha Sureclick Evolocumab Brand 42 $45,000
Repatha Syringe Evolocumab Brand 34 $37,180
Praluent Pen Alirocumab Brand 19 $14,677
Atorvastatin Calcium Generic 541 $4,958
Metoprolol Succinate Generic 316 $4,145
Clopidogrel Clopidogrel Bisulfate Brand 271 $3,706

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$322,999

Medicare's payments for the services billed

Medicare patients

2,430

Average age 76

Services billed

5,425

1,390 women, 1,040 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 47%
Diabetes 39%
Chronic kidney disease 38%
Atrial fibrillation 37%
Heart failure 36%
Depression 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

199 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record